DNER and acute lymphoblastic leukemia: Targeted inhibition of BET bromodomain binding is potentially therapeutic for glioblastoma, lung adenocarcinoma, ALL (acute lymphoblastic leukemia) and MLL (mixed-lineage leukemia) [81,82,83,84,85].